Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 27;15(2):273-286.
doi: 10.4240/wjgs.v15.i2.273.

Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis

Affiliations

Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis

Aaron Jl Lee et al. World J Gastrointest Surg. .

Abstract

Background: Research on long-term survival after resection of giant (≥ 10 cm) and non-giant hepatocellular carcinoma (HCC) (< 10 cm) has produced conflicting results.

Aim: This study aimed to investigate whether oncological outcomes and safety profiles of resection differ between giant and non-giant HCC.

Methods: PubMed, MEDLINE, EMBASE, and Cochrane databases were searched. Studies designed to investigate the outcomes of giant vs non-giant HCC were included. The primary endpoints were overall survival (OS) and disease-free survival (DFS). The secondary endpoints were postoperative complications and mortality rates. All studies were assessed for bias using the Newcastle-Ottawa Scale.

Results: 24 retrospective cohort studies involving 23747 patients (giant = 3326; non-giant = 20421) who underwent HCC resection were included. OS was reported in 24 studies, DFS in 17 studies, 30-d mortality rate in 18 studies, postoperative complications in 15 studies, and post-hepatectomy liver failure (PHLF) in six studies. The HR was significantly lower for non-giant HCC in both OS (HR 0.53, 95%CI: 0.50-0.55, P < 0.001) and DFS (HR 0.62, 95%CI: 0.58-0.84, P < 0.001). No significant difference was found for 30-d mortality rate (OR 0.73, 95%CI: 0.50-1.08, P = 0.116), postoperative complications (OR 0.81, 95%CI: 0.62-1.06, P = 0.140), and PHLF (OR 0.81, 95%CI: 0.62-1.06, P = 0.140).

Conclusion: Resection of giant HCC is associated with poorer long-term outcomes. The safety profile of resection was similar in both groups; however, this may have been confounded by reporting bias. HCC staging systems should account for the size differences.

Keywords: Giant hepatocellular carcinoma; Hepatectomy; Meta-analysis; Resection.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interests in the subject matter or materials discussed in this manuscript.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow diagram.
Figure 2
Figure 2
Overall survival curves, numbers-at-risk table and Forest plot. A: Overall survival (OS) curves and numbers-at-risk table for giant vs non-giant hepatocellular carcinoma from reconstructed individual patient data; B: OS forest plot. HCC: Hepatocellular carcinoma; HR: Hazard ratio; RMST: Restricted mean survival time.
Figure 3
Figure 3
Disease-free survival curve, numbers-at-risk table and Forest plot. A: Disease-free survival (DFS) curves and numbers-at-risk table for giant vs non-giant hepatocellular carcinoma from reconstructed individual patient data; B: DFS forest plot. HCC: Hepatocellular carcinoma; HR: Hazard ratio; RMST: Restricted mean survival time.
Figure 4
Figure 4
Forest plots for morbidity and 30-d mortality. A: Forest plot of the 30-d mortality rate; B: Forest plot of the postoperative complication rate; C: Forest plot of post-hepatic liver failure rate. HCC: Hepatocellular carcinoma.

References

    1. Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898–1907. - PMC - PubMed
    1. Sheriff S, Madhavan S, Lei GY, Chan YH, Junnarkar SP, Huey CW, Low JK, Shelat VG. Predictors of mortality within the first year post-hepatectomy for hepatocellular carcinoma. J Egypt Natl Canc Inst. 2022;34:14. - PubMed
    1. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73 Suppl 1:4–13. - PMC - PubMed
    1. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599–616. - PMC - PubMed
    1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604. - PMC - PubMed